Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer
Pharma giant Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Over the past couple of months, Cramer has turned optimistic about the company.
Johnson & Johnson (JNJ)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 8,866,207 | $1,834,861,808 | +5% | 0.63% |
| 2. | GQG Partners Rajiv Jain | 7,752,266 | $1,604,336,241 | +29% | 2.64% |
| 3. | AQR Capital Management Cliff Asness | 3,876,221 | $802,183,859 | -11% | 0.42% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 3,668,263 | $759,147,029 | +3% | 0.69% |
| 5. | 3,072,600 | $635,874,570 | -14% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $242.70 | 20,521 | $4,980,446.70 | 25,698 | 2026-02-17 | Filing | |
| $243.71 | 22,191 | $5,408,168.61 | 25,020 | 2026-02-13 | Filing | |
| $243.76 | 19,368 | $4,721,143.68 | 25,020 | 2026-02-13 | Filing | |
| $242.68 | 24,961 | $6,057,535.48 | 14,000 | 2026-02-17 | Filing | |
| $242.75 | 33,386 | $8,104,451.50 | 38,961 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 240,349,660 | $49,740,362,171 | 0.72% | |
| 2. | 208,781,159 | $43,207,260,821 | 0.73% | |
| 3. | 133,869,843 | $27,704,364,009 | 0.93% | |
| 4. | 58,558,238 | $12,118,628,064 | 0.76% | |
| 5. | 57,953,747 | $11,967,946,703 | 0.74% |
News See All
10 Stocks on Jim Cramer's Radar
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the impact that Anthropic was having on the enterprise software market.
Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study
Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy.
Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds?
Johnson & Johnson (NYSE:JNJ) is one of the best medical research stocks to buy according to hedge funds.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
10 Most Profitable Mega Cap Stocks to Buy
In any economy, mega-cap or the largest companies act as the backbone of financial markets due to their strong fundamentals and dominant market positions.
Jim Cramer Commented on These 14 Stocks
There is a reason I always hesitate to recommend the hottest stocks in the market, the ones with the parabolic moves, the monstrous one-day gains.
RBC Sees Johnson & Johnson (JNJ) Well Positioned to Manage Legal Overhang
On February 3, RBC Capital raised its price target on Johnson & Johnson (NYSE:JNJ) to $255 from $240 and reiterated an Outperform rating.
15 Best Wide Moat Dividend Stocks to Invest in
Wide-moat stocks are companies with durable advantages that help them keep competitors at bay. According to an S&P Global report, a large market share can be a sign of a strong economic moat.
BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 - Here's Why
Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in.
Hedge Fund Resource Center Billionaire Hedge Funds
